Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis



Status:Completed
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - 80
Updated:4/21/2016
Start Date:November 2010
End Date:March 2016

Use our guide to learn which trials are right for you!

International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis

The primary purpose of this study is to assess the efficacy and safety of treatment with
Kiacta in adult patients with AA Amyloidosis.


Inclusion Criteria:

- females must be of nonchildbearing potential (more than 1 yr postmenopausal)or use
effective contraception for at least 2 months prior to the baseline visit and through
30 days after the last dose of study medication

- confirmed diagnosis of AA amyloidosis demonstrated by positive biopsy using congo red
staining and immunohistochemistry or immunoelectronmicroscopy. Mass spectroscopy will
be used upon approval of the sponsor on a case to case basis.

- persistent proteinuria greater than 1 g/24h at 2 distinct 24-hr urine collections

- must have CrCl greater than 25 ml/min/1.73 m2 at 2 distinct 24 hr urine collections

Exclusion Criteria:

- evidence or suspicion of chronic kidney disease secondary to a disease other than AA
amyloidosis (eg, diabetes, long-standing uncontrolled hypertension, polycystic kidney
disease, recurring polynephritis, or systemic lupus erythematosus)

- history of kidney transplantation

- evidence or suspicion of a cause of potentially reversible acute renal failure within
3 months prior to baseline visit

- presence of concomitant diseases or medication that could interfere with the
interpretation of study results or compromise patient safety

- presence of condition that could reduce life expectancy to less than 2 yrs

- Type 1 or 2 diabetes mellitus

- significant hepatic enzyme elevation

- unstable angina, myocardial infarction, coronary artery bypass graft surgery, or
percutaneous transluminal coronary angioplasty within 6 months prior to the baseline
visit; presence of NY Heart Assoc class III or IV heart failure

- presence of, or history of stroke or transient ischemic attack within 6 months prior
to baseline visit

- initiation of, or any changes in, angiotensin converting enzyme inhibitor,
angiotensin II receptor antagonist therapy, or renin inhibitor within 3 months prior
to baseline visit

- initiation of, or any changes in, cytotoxic agents, anti-tumor necrosis factor
agents, anti interleukin-1 or 6 agents, or colchicine therapy within 3 months prior
to baseline visit

- previous use of Kiacta

- history of malignancy within 5 yrs prior to study entry, except for cervical
carcinoma in situ, nonmelanomatous carcinoma of the skin, or ductal carcinoma in situ
of the breast that has been surgically cured

- use of investigational drug within 30 days prior to the first screening visit

- active alcohol and/or drug abuse
We found this trial at
4
sites
Boston, Massachusetts 02118
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Glendale, California 91204
?
mi
from
Glendale, CA
Click here to add this to my saved trials
Leuven, 3001
?
mi
from
Leuven,
Click here to add this to my saved trials